(Q39095733)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Interrogating open issues in cancer precision medicine with patient-derived xenografts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Joan Seoane

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Violeta Serra

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Annette T. Byrne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Daniela Annibali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Joaquin Arribas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Robert B. Clarke

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

George Coukos

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Luisa Lanfrancone

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Elisabetta Marangoni

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jean-Christophe Marine

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Enzo Medico

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Héctor G. Palmer

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Sergio Roman-Roman

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Laura Soucek

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Livio Trusolino

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

3

Frédéric Amant

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

41

Andrea Bertotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

24

Gunhild Mari Mælandsmo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

30

Daniel S Peeper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Alejandro Piris-Gimenez

32

Alejandro Piris-Gimenez

1 reference

9 April 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

Els Hermans

17

Els Hermans

1 reference

9 April 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

Emilie Vinolo

40

Emilie Vinolo

1 reference

9 April 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

Kristel Kemper

22

Kristel Kemper

1 reference

9 April 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

Dominique Vanhecke

38

Dominique Vanhecke

1 reference

9 April 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

author name string

Denis G Alférez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Alejandra Bruna

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Eva Budinská

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

David K Chang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Hans Clevers

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Virginie Dangles-Marie

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

S Gail Eckhardt

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Eva Gonzalez-Suarez

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Manuel Hidalgo

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Steven de Jong

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jos Jonkers

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jens Henrik Norum

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Pier Giuseppe Pelicci

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Oscar M Rueda

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Alberto Villanueva

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Carlos Caldas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Monika A Jarzabek

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

language of work or name

English

0 references

publication date

20 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

254-268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2016.140

9 April 2020

exact match

0 references

cites work

Translating cancer research into targeted therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Trial watch: Phase II failures: 2008-2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Trial watch: phase II and phase III attrition rates 2011-2012.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The genomic landscape of response to EGFR blockade in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived xenograft models: an emerging platform for translational cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived tumor xenografts: transforming clinical samples into mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived tumour xenografts as models for oncology drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Preclinical mouse cancer models: a maze of opportunities and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Tumorigenesis: it takes a village

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The implications of clonal genome evolution for cancer medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Evolution of the cancer stem cell model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Intra-tumour heterogeneity: a looking glass for cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Genetic clonal diversity predicts progression to esophageal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A new genome-driven integrated classification of breast cancer and its implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The life history of 21 breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A new model of patient tumor-derived breast cancer xenografts for preclinical assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Biology, detection, and clinical implications of circulating tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Metastatic colonization by circulating tumour cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Stem cells, cancer, and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Identification of human pancreatic cancer stem cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Prospective identification of tumorigenic breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Cancer stem cell niche: the place to be

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Intracellular autofluorescence: a biomarker for epithelial cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Cancer stem cells: impact, heterogeneity, and uncertainty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived xenografts for individualized care in advanced sarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Effect of cellular senescence on the growth of HER2-positive breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Origin of the vasculature supporting growth of primary patient tumor xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Engineering humanized mice for improved hematopoietic reconstitution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Human hemato-lymphoid system mice: current use and future potential for medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Construction of orthotopic xenograft mouse models for human pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Imaging preclinical tumour models: improving translational power

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A new mouse model for the study of human breast cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Circulating tumor cells: a multifunctional biomarker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Challenges in circulating tumour cell research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Analysis of circulating tumor cells derived from advanced gastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Establishment and characterization of a cell line from human circulating colon cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The isolation and characterization of CTC subsets related to breast cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Molecular analysis of circulating tumour cells-biology and biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

HER2 expression identifies dynamic functional states within circulating breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Lessons from the cancer genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

HER2 activating mutations are targets for colorectal cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Organoid models of human and mouse ductal pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Organoid cultures derived from patients with advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Prospective derivation of a living organoid biobank of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The APL paradigm and the "co-clinical trial" project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Molecular causes of the aberrant choline phospholipid metabolism in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

31P MRSI and 1H MRS at 7 T: initial results in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Stromal contribution to the colorectal cancer transcriptome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Of mice and not men: differences between mouse and human immunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

LAS: a software platform to support oncological data management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Current advances in humanized mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Xenome--a tool for classifying reads from xenograft samples.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Humanized mice for immune system investigation: progress, promise and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Development of a human adaptive immune system in cord blood cell-transplanted mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγ(null) humanized mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Development and function of human innate immune cells in a humanized mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.140

Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma

31 March 2020

1 reference

12 December 2020

Scatter factor and hepatocyte growth factor: activities, properties, and mechanism

1 reference

12 December 2020

Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.

1 reference

12 December 2020

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104906%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference